These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34272891)

  • 1. Comparative in silico prediction of P-glycoprotein-mediated transport for 2010-2020 US FDA-approved drugs using six Web-tools.
    Guéniche N; Huguet A; Bruyere A; Habauzit D; Le Hégarat L; Fardel O
    Biopharm Drug Dispos; 2021 Sep; 42(8):393-398. PubMed ID: 34272891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
    Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
    Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
    Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q
    PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
    Tachibana T; Kato M; Takano J; Sugiyama Y
    Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PgpRules: a decision tree based prediction server for P-glycoprotein substrates and inhibitors.
    Wang PH; Tu YS; Tseng YJ
    Bioinformatics; 2019 Oct; 35(20):4193-4195. PubMed ID: 30918935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
    Miyake T; Tsutsui H; Haraya K; Tachibana T; Morimoto K; Takehara S; Ayabe M; Kobayashi K; Kazuki Y
    Br J Pharmacol; 2021 Nov; 178(21):4335-4351. PubMed ID: 34232502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an
    Watanabe R; Esaki T; Ohashi R; Kuroda M; Kawashima H; Komura H; Natsume-Kitatani Y; Mizuguchi K
    J Med Chem; 2021 Mar; 64(5):2725-2738. PubMed ID: 33619967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.
    Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo.
    Zhou T; Arya V; Zhang L
    J Clin Pharmacol; 2019 Aug; 59(8):1049-1060. PubMed ID: 30924955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A regulatory viewpoint on transporter-based drug interactions.
    Zhang L; Zhang YD; Strong JM; Reynolds KS; Huang SM
    Xenobiotica; 2008 Jul; 38(7-8):709-24. PubMed ID: 18668428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies.
    Prajapati R; Singh U; Patil A; Khomane KS; Bagul P; Bansal AK; Sangamwar AT
    J Comput Aided Mol Des; 2013 Apr; 27(4):347-63. PubMed ID: 23612916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.
    Ellens H; Deng S; Coleman J; Bentz J; Taub ME; Ragueneau-Majlessi I; Chung SP; Herédi-Szabó K; Neuhoff S; Palm J; Balimane P; Zhang L; Jamei M; Hanna I; O'Connor M; Bednarczyk D; Forsgard M; Chu X; Funk C; Guo A; Hillgren KM; Li L; Pak AY; Perloff ES; Rajaraman G; Salphati L; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yamagata T; Lee CA
    Drug Metab Dispos; 2013 Jul; 41(7):1367-74. PubMed ID: 23620486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotropic drug-drug interactions involving P-glycoprotein.
    Akamine Y; Yasui-Furukori N; Ieiri I; Uno T
    CNS Drugs; 2012 Nov; 26(11):959-73. PubMed ID: 23023659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
    Muenster U; Grieshop B; Ickenroth K; Gnoth MJ
    Pharm Res; 2008 Oct; 25(10):2320-6. PubMed ID: 18523872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
    Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
    Akamine Y; Yasui-Furukori N; Uno T
    Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y; Hu ZY
    Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.